Evidence map›Paper›PMID 32748577›Full record

ArticleJournal of Zhejiang University. Science. B

Microencapsulation of immunoglobulin Y: optimization with response surface morphology and controlled release during simulated gastrointestinal digestion.

Jin Zhang, Huan-Huan Li, Yi-Fan Chen, Li-Hong Chen, Hong-Gang Tang, Fan-Bin Kong, Yun-Xin Yao, Xu-Ming Liu, Qian Lan, Xiao-Fan Yu

Abstract read
In one paragraph

Article in Journal of Zhejiang University. Science. B. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Improvement of neutral protease activity ofJournal of Zhejiang University. Science. B · 2025
    Article
  2. Latest Findings in Immunoglobulin Y Technologies and Applications.International journal of molecular sciences · 2025
    Review
  3. Process optimization of co-fermentation natto withJournal of food science and technology · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jin ZhangInstitute of Food Science, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China.
Huan-Huan LiInstitute of Food Science, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China.
Yi-Fan ChenInstitute of Food Science, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China.
Li-Hong ChenInstitute of Food Science, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China.
Hong-Gang TangInstitute of Food Science, Zhejiang Academy of Agricultural Sciences, Hangzhou 310021, China.
Fan-Bin KongDepartment of Food Science and Technology, The University of Georgia, Athens GA 30602, USA.
Yun-Xin YaoZhejiang AGS Biotech Co., Ltd., Huzhou 313100, China.
Xu-Ming LiuBeijing Deqingyuan Food Co., Ltd., Beijing 100094, China.
Qian LanCollage of Chemistry and Bioengineering, Hunan University of Science and Engineering, Yongzhou 425199, China.
Xiao-Fan YuCollage of Chemistry and Bioengineering, Hunan University of Science and Engineering, Yongzhou 425199, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunoglobulin Y (IgY) is an effective orally administered antibody used to protect against various intestinal pathogens, but which cannot tolerate the acidic gastric environment. In this study, IgY was microencapsulated by alginate (ALG) and coated with chitooligosaccharide (COS). A response surface methodology was used to optimize the formulation, and a simulated gastrointestinal (GI) digestion (SGID) system to evaluate the controlled release of microencapsulated IgY. The microcapsule formulation was optimized as an ALG concentration of 1.56% (15.6 g/L), COS level of 0.61% (6.1 g/L), and IgY/ALG ratio of 62.44% (mass ratio). The microcapsules prepared following this formulation had an encapsulation efficiency of 65.19%, a loading capacity of 33.75%, and an average particle size of 588.75 μm. Under this optimum formulation, the coating of COS provided a less porous and more continuous microstructure by filling the cracks on the surface, and thus the GI release rate of encapsulated IgY was significantly reduced. The release of encapsulated IgY during simulated gastric and intestinal digestion well fitted the zero-order and first-order kinetics functions, respectively. The microcapsule also allowed the IgY to retain 84.37% immune-activity after 4 h simulated GI digestion, significantly higher than that for unprotected IgY (5.33%). This approach could provide an efficient way to preserve IgY and improve its performance in the GI tract.

Indexed as

Alginic AcidChitinChitosanDelayed-Action PreparationsDigestionDrug CompoundingDrug LiberationGastrointestinal TractImmunoglobulinsOligosaccharidesAlginic AcidChitinChitosanDelayed-Action PreparationsIgYImmunoglobulinsoligochitosanOligosaccharidesImmunoglobulin Y (IgY); Microencapsulation; Chitooligosaccharide (COS); Response surface methodology (RSM); Controlled release; Simulated gastrointestinal digestion (SGID)

Identifiers

PMID32748577
PMCPMC7445086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.